TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3757511
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose regimen (400 mg/day RU 486 X 4 days or 200 mg/day X 4 days)
Study: 3757511
Drug: Medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose regimen (100 mg/day X 7 days)
Study: 3757511
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (including both high and medium doses)
Study: 28254462
Drug: ASP3652 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP3652 300 mg twice daily
Study: 27323445
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (Zhongwan, Tianshu, Daheng, Daimai, Shuidao, Waiguan, Zulinqi with electroacupuncture stimulation at 2 Hz/100 Hz, 4‐8 mA for 20 min, once every other day for 8 weeks)
Study: 27323445
Drug: Health education
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health education (restraining wine or liquor and salt intake, stopping smoking, increasing physical activities, regular daily life habit)
Study: 24198629
Drug: Silodosin 8
Normalized name: silodosin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silodosin 8 mg once daily for 12 weeks
Study: 24612148
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg once daily for 12 weeks
Study: 20687837
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of arterolane once daily for 7 days
Study: 20687837
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of arterolane once daily for 7 days
Study: 20687837
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of arterolane once daily for 7 days
Study: 18984430
Drug: Indapamide (IND)
Normalized name: Indapamide
DrugBank: Indapamide (DB00808)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indapamide (IND) 2.5 mg once daily
Study: 18984430
Drug: Bendroflumethiazide (BDZ)
Normalized name: Bendroflumethiazide
DrugBank: Bendroflumethiazide (DB00436)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bendroflumethiazide (BDZ) 2.5 mg once daily
Study: 15836686
Drug: AAI-guided sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AAI-guided sevoflurane titration (target = 20 +/- 5)
Study: 15836686
Drug: Clinical signs-guided
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical signs-guided sevoflurane titration
Study: 11918749
Drug: L-Arg supplementation
Normalized name: L-Arg
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: L-Arg supplementation (IV for three days)
Study: 11918749
Drug: L-Arg administration
Normalized name: L-Arg
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: L-Arg administration
Study: 10341399
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of maternal age, fetal nuchal translucency thickness, maternal serum free beta‐hCG, and PAPP‐A
Study: 8730942
Drug: Dothiepin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dothiepin (150 mg/day)
Study: 23672237
Drug: Cilostazol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol (100 mg orally twice daily for 24 weeks)
Study: 15968883
Drug: Ciclesonide (640
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclesonide (640 microg ex‐actuator, equivalent to 800 microg ex‐valve, via hydrofluoroalkane metered‐dose inhaler)
Study: 15968883
Drug: Erythromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (500 mg PO)
Study: 15968883
Drug: Combined administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined administration of ciclesonide and erythromycin
Study: 12056936
Drug: Civamide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Civamide (100 microL of 0.025% civamide, 25 microg) once daily for 7 days
Study: 12056936
Drug: Vehicle (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (100 microL) once daily for 7 days
Study: 7862216
Drug: Paclitaxel 135
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 135 mg/m2
Study: 8708510
Drug: Paclitaxel (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (both doses)
Study: 8708510
Drug: Paclitaxel (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (high dose)
Study: 1746996
Drug: Famotidine 20
Normalized name: famotidine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 20 mg BID
Study: 1746996
Drug: Famotidine 40
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 40 mg HS
Study: 1746996
Drug: Famotidine 40
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 40 mg HS and Famotidine 20 mg BID
Study: 6213641
Drug: Preparation (informative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation (informative preoperative interview)
Study: 30823947
Drug: LISA (less
Approvals — FDA: no, EMA: no, PMDA: no
Description: LISA (less invasive surfactant administration)
Study: 30823947
Drug: INSURE (INtubation
Approvals — FDA: no, EMA: no, PMDA: no
Description: INSURE (INtubation SURfactant administration and Extubation)
Study: 27973989
Drug: Saccharomyces boulardii
Normalized name: Saccharomyces boulardii
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saccharomyces boulardii (SB) plus Amoxicillin-Clavulanate (AC)
Study: 27973989
Drug: Amoxicillin-Clavulanate (AC)
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-Clavulanate (AC) alone
Study: 21494229
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of diet and exercise (D+E)
Study: 19466657
Drug: Partial or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial or subtotal thyroid gland removal treatment (group B)
Study: 9615847
Drug: Preoperative ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative ketoprofen 100 mg i.v., 12 mg/h during surgery and for 48 hours afterwards
Study: 9615847
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg ketoprofen as a bolus injection before the end of surgery, thereafter 12 mg/h ketoprofen continuously for 48 hours
Study: 3325229
Drug: Isosorbide-5-mononitrate (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide-5-mononitrate (20 mg)
Study: 24832384
Drug: Extended-release niacin/laropiprant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release niacin/laropiprant
Study: 19486449
Drug: Pantoprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole (40 mg/day) for 28 days
Study: 19486449
Drug: Ranitidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (300 mg o.d.) for 60 days
Study: 9530125
Drug: daily exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily exercise program (55% peak oxygen uptake)
Study: 8556776
Drug: Hydrochlorothiazide (25-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (25-50 mg daily for at least six months)
Study: 8556776
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (500 mg daily for 30 days)
Study: 8556776
Drug: Magnesium chloride
Normalized name: Magnesium Chloride
DrugBank: Magnesium chloride (DB09407)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium chloride supplementation (1 g daily for 30 days)
Study: 323705
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg of estrogen
Study: 323705
Drug: 5.0 mg
Normalized name: RUXOLITINIB 5.0 mg ORAL TABLET [JAKAFI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 mg of estrogen
Study: 323705
Drug: 1.8 g
Normalized name: Calciquid, 1.8 g/5 mL oral syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 g of clofibrate
Study: 28871620
Drug: Oropharyngeal surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oropharyngeal surfactant (1.5 mL of Curosurf) with sustained inflation manoeuvre (SIM)
Study: 27919362
Drug: OM3‐CA (omega‐3
Approvals — FDA: no, EMA: no, PMDA: no
Description: OM3‐CA (omega‐3 carboxylic acids) 2, 3, or 4 g/d
Study: 24534599
Drug: Optimal medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical therapy goals (aspirin use, blood pressure control, cholesterol levels, glucose levels, nonsmoking status, body mass index, exercise frequency)
Study: 15893104
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment control group (DTC)
Study: 9477013
Drug: Scaling with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling with systemic metronidazole plus amoxicillin and supragingival irrigation with chlorhexidine digluconate
Study: 11281339
Drug: Lisinopril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (20 mg/day)
Study: 7662221
Drug: Hydrochlorothiazide (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (12.5 mg/day)
Study: 2527541
Drug: Cilazapril 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril 1.25 or 2.5 mg
Study: 824468
Drug: Low-dose penicillin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose penicillin (procaine penicillin G, 600,000 units intramuscularly, every 12 hours for up to ten days)
Study: 824468
Drug: High-dose penicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose penicillin (procaine penicillin G, same regimen as low-dose plus intravenous aqueous penicillin G, 10 million units daily for the first three days)
Study: 824468
Drug: High-dose penicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose penicillin
Study: 824468
Drug: Low-dose penicillin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose penicillin
Study: 824468
Drug: Low-dose penicillin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose penicillin and high-dose penicillin
Study: 23401601
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg loading dose of leflunomide (LEF) for 3 days, followed by 20 mg LEF daily for 3 months
Study: 23401601
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg fixed dose of leflunomide (LEF) for 3 days, followed by 20 mg LEF daily for 3 months
Study: 23401601
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (loading-dose and fixed-dose)
Study: 19419359
Drug: Spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anesthesia (SA) with bupivacaine 15 mg, 0.15 mg of intrathecal morphine and 15 microg of fentanyl
Study: 26363481
Drug: Transvaginal cervical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transvaginal cervical length (TVCL) assessment and digital exams monthly from 16‐28 weeks with standard management algorithm for activity restriction and cerclage
Study: 26363481
Drug: Monthly digital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly digital cervical examinations without routine TVCL ultrasound
Study: 16859225
Drug: Neomycin-polymyxin solution
Normalized name: neomycin / polymyxin B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neomycin-polymyxin solution
Study: 12590375
Drug: Clonidine 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 0.15 mg/day
Study: 7572582
Drug: Mibefradil 150
Normalized name: mibefradil
DrugBank: Mibefradil (DB01388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mibefradil 150 mg
Study: 8408529
Drug: RU486 (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU486 (600 mg)
Study: 8408529
Drug: RU486 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU486 (3 x 25 mg)
Study: 8408529
Drug: RU486 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU486 (25 mg)
Study: 15722780
Drug: Drug therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapies for complex regional pain syndrome
Study: 15722780
Drug: Pharmacotherapy coupled
Normalized name: IMMUNOGLOBULIN G4-KAPPA/G4-LAMBDA, ANTI-(HOMO SAPIENS GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D)), AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODY, BISPECIFIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy coupled with functional restoration and interdisciplinary approach
Study: 12229131
Drug: Morphine (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (IV PCA) alone (2 mg bolus, 10-minute lock-out interval, 10 mg/hour limit for 48 hours)
Study: 10102019
Drug: Conventional cranial
Normalized name: geranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional cranial irradiation (CRT) regimen (L874A and I874A) - 18-Gy CRT plus 3 doses of intrathecal (i.t.) MTX
Study: 10102019
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate (HDMTX) regimen without CRT (L874B and I874B) - 3 courses of HDMTX at 2 g/m2 plus 13 doses of ITMTX or 4 courses of HDMTX at 4.5 g/m2 plus 1 dose of ITMTX
Study: 10102019
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate (HDMTX) regimen without CRT (I874B)
Study: 10102019
Drug: Intensive systemic
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive systemic chemotherapy with extended i.t. injections of MTX plus cytarabine
Study: 10102019
Drug: Cranial irradiation
Normalized name: geranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranial irradiation (18-Gy or 24-Gy) with intensive systemic chemotherapy
Study: 2265371
Drug: HPP 3
Normalized name: 4-HPP
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HPP 3 x 300 mg po, days 1-5, 5-FU 800 mg/m2 push iv, days 3-5 and DDP 50 mg/m2 d6
Study: 2265371
Drug: 5-FU alone
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU alone 500 mg/m2 push iv days 1-5
Study: 7004247
Drug: Cinnarizine in
Normalized name: Product containing cinnarizine in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnarizine in combination with phenylpropanolamine
Study: 28248418
Drug: Customized behavioral
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Customized behavioral urinary incontinence treatments combined with physical activity (150 minutes of weekly walking and twice weekly strength training classes)
Study: 28248418
Drug: Customized behavioral
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Customized behavioral urinary incontinence treatments combined with physical activity
Study: 25271779
Drug: Group cognitive-behavioral
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive-behavioral therapy (22 sessions)
Study: 25271779
Drug: Group supportive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group supportive therapy (control, 22 sessions)
Study: 17596103
Drug: Vildagliptin 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin 25 mg and 100 mg
Study: 14872477
Drug: Escalating doses
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating doses of IM methotrexate up to 45 mg/week
Study: 14872477
Drug: 15 mg/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/week IM methotrexate with monthly placebo escalation
Study: 11163032
Drug: Allopurinol (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (administered with pre-medication)
Study: 31180297
Drug: Epoetin beta
Normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Epoetin beta treatment to a hemoglobin target level of 11.5 to 13.5 g/dL
Study: 31180297
Drug: Epoetin beta
Normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Epoetin beta treatment
Study: 16681436
Drug: Adrenocorticotrophic hormone
Normalized name: Adrenocorticotrophic hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenocorticotrophic hormone (ACTH)(1‐24) 1 mg i.m. daily for 4 days
Study: 16681436
Drug: Cortisol 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol 50 mg i.m. t.i.d. for 4 days
Study: 9771317
Drug: Extubation while
Normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extubation while sedated (propofol 1‐3 mg kg‐1 h‐1)
Study: 3063797
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg sublingually
Study: 21311184
Drug: Oral mycophenolate
Normalized name: mycophenolate
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral mycophenolate mofetil (MMF) 1.0 g/day (1.5 g/day for patients >70 kg)
Study: 21311184
Drug: Intravenous cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclophosphamide (IVC) 1.0 g per pulse (0.8 g for patients <50 kg)
Study: 21121175
Drug: Amantadine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine (100 mg)
Study: 2570799
Drug: terfenadine, 60
Normalized name: Terfenadine, 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: terfenadine, 60 mg
Study: 8201490
Drug: chlorpheniramine, 4
Normalized name: Chlorpheniramine, 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: chlorpheniramine, 4 mg
Study: 3276299
Drug: Controlled-release carbidopa-levodopa
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release carbidopa-levodopa (CR-2 or CR-3)
Study: 3276299
Drug: Standard carbidopa-levodopa
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard carbidopa-levodopa (Sinemet, 25 mg/100 mg)
Study: 21167330
Drug: Multi-component physical
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-component physical activity intervention including daily physical education with at least 10 min of jumping or strength training exercises of various intensities.
Study: 1519829
Drug: Control solutions
Normalized name: Accu-Chek Comfort Curve Control Solutions
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control solutions
Study: 12572377
Drug: Yishen Jiedu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yishen Jiedu Recipe (YSJDR) in addition to low-protein diet and blood pressure controlling therapy
Study: 12572377
Drug: Low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein diet and blood pressure controlling therapy only
Study: 26673391
Drug: H7N9 live
Normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: H7N9 live attenuated influenza vaccine
Study: 20307166
Drug: Smoking intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking intervention (eight-session individually administered trial)
Study: 18584479
Drug: Soy extract
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy extract supplementation (3 Evestrel capsules, providing a total of 112.5 mg isoflavones aglycone eq/day) for 3 days before prostate surgery
Study: 16875160
Drug: PGE1 (Prostavasin)
Normalized name: PGE1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PGE1 (Prostavasin) infusion at a dose of 0.02 mg/kg b.m./min
Study: 12800417
Drug: Astragalus Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astragalus Injection (AI) 30 ml (equivalent to 60 g crude drug) administered intravenously once a day for 20 days
Study: 12800417
Drug: Nitroglycerine injection
Normalized name: nitroglycerin Injection
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerine injection 10 mg administered intravenously once a day for 20 days (Control group)
Study: 8872850
Drug: Co-amilozide (thiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-amilozide (thiazide diuretic)
Study: 8157550
Drug: Ciprofloxacin 400
Normalized name: ciprofloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 400 mg i.v.
Study: 1510426
Drug: Ciprofloxacin oral
Normalized name: ciprofloxacin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin oral doses (500 mg and 750 mg)
Study: 1510426
Drug: Ciprofloxacin i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin i.v. dosing
Study: 6682776
Drug: Cis-diamminedichloroplatinum (II)
Normalized name: CIS-DIAMMINEDICHLOROPLATINUM
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cis-diamminedichloroplatinum (II) (CDDP) at various doses (20 mg/m2, 25-50 mg/m2, 70-120 mg/m2)
Study: 6682776
Drug: Rapid infusion
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid infusion of a single high dose of CDDP
Study: 6682776
Drug: Daily low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily low dose of CDDP for 5 days
Study: 6682776
Drug: Single low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single low dose of CDDP
Study: 26199465
Drug: Intranasal Dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal Dexmedetomidine (DEX)
Study: 30450972
Drug: Dry heat
Normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dry heat treatment (fluidotherapy)
Study: 27656053
Drug: Alprazolam and
Normalized name: Alprazolam and propranolol only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam and Diclofenac Potassium (pre-medication)
Study: 27656053
Drug: Gow-Gates technique
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gow-Gates technique with pre-medication
Study: 27656053
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (without pre-medication)
Study: 24864502
Drug: Solcoseryl Eye
Normalized name: Solcoseryl
DrugBank: Solcoseryl (DB15794)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solcoseryl Eye Gel